Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhu, Hai-Dong
NCT05472896: TACE With Dicycloplatin(TP21) in Unresectable HCC	Recruiting	3	332	RoW	cTACE, Dicycloplatin (TP21), Epirubicin	Gao-jun Teng	Hepatocellular Carcinoma	06/24	06/24
CHANCE 2203, NCT05348811: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC	Recruiting	2	32	RoW	HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab	Zhongda Hospital	Cholangiocarcinoma	06/23	07/23
CHANCE001, NCT04975932: Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study	Completed	N/A	826	RoW	TACE+ICIs, TACE	Zhongda Hospital	Hepatocellular Carcinoma	05/22	02/23
NCT05631613: Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma	Recruiting	N/A	40	RoW	cTACE(conventional transarterial chemoembolization)	Zhongda Hospital	Hepatocellular Carcinoma	03/23	04/23
CHANCE2201, NCT05332821: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC	Recruiting	N/A	474	RoW	PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE	Zhongda Hospital	Hepatocellular Carcinoma	08/23	08/23
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC	Recruiting	N/A	220	RoW	PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE	Zhongda Hospital	Hepatocellular Carcinoma	08/23	09/23
NCT06190665: DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC	Recruiting	N/A	188	RoW	DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres	Zhongda Hospital	Hepatocellular Carcinoma	12/25	12/26
ST-Y90-CP01, NCT06447727: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM	Recruiting	N/A	30	RoW	SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab	Zhongda Hospital	Colorectal Cancer Metastatic	11/25	11/25